Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report

Chung Fu Lin, Szu Yu Liu, Tzu Kun Lo, Julia Yu Yun Lee, Po Lan Su

研究成果: Article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)-mutant advanced-stage non-small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first-generation EGFR-TKI use than with second-generation inhibitors. Herein, we report a case of a patient with advanced-stage EGFR-mutant NSCLC who developed drug reaction with eosinophilia and systemic symptoms (DRESS) after receiving treatment with afatinib. The patient was successfully rechallenged with erlotinib, without manifestations of skin rash in the following 6 months. Hence, erlotinib may be considered a potential substitute for other EGFR-TKIs following DRESS occurrence.

原文English
頁(從 - 到)494-496
頁數3
期刊Thoracic Cancer
13
發行號3
DOIs
出版狀態Published - 2022 2月

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 肺和呼吸系統醫學

指紋

深入研究「Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report」主題。共同形成了獨特的指紋。

引用此